WHO panel recommends against use of remdesivir for COVID-19 patients

A World Health Organization (WHO) panel recommended against using remdesivir in hospitalized patients with COVID-19 because there is no e...


A World Health Organization (WHO) panel recommended against using remdesivir in hospitalized patients with COVID-19 because there is no evidence it improves survival.

The recommendation breaks with the Trump administration, as remdesivir recently became the only drug approved by the Food and Drug Administration to treat hospitalized COVID-19 patients.

The WHO panel also found the drug, which is delivered intravenously, had no real impact on whether patients would need to be put on ventilators.

The recommendation from the WHO Guideline Development Group was published late Thursday night in the international journal The BMJ.

The recommendation was based on data from four international randomized trials involving more than 7,000 patients hospitalized for COVID-19.

According to the panel, the evidence did not prove that remdesivir has no benefit. Instead, there is no evidence based on currently available data that the drug improves important patient outcomes.

Remdesivir has received worldwide attention as a potentially effective treatment for severe COVID-19, but the evidence has been decidedly mixed.

One gold-standard trial from the National Institutes of Health found remdesivir helped patients leave the hospital faster than if they received a placebo. 

But notably, the WHO solidarity trial, billed as the world’s largest randomized control trial on COVID-19 therapeutics, found no impact on the survival of COVID-19 patients or the length of time they stay in the hospital. 

Remdesivir received emergency use authorization from the Food and Drug Administration on May 1 after it showed modest results in reducing the hospitalizations of patients with severe cases of COVID-19.

It gained full approval last month.

Remdesivir was one of a number of medications given to President TrumpDonald John TrumpBen Carson says he’s ‘out of the woods’ after being ‘extremely sick’ with COVID-19 Biden will receive @POTUS Twitter account on Jan. 20 even if Trump doesn’t concede, company says Trump to participate in virtual G-20 summit amid coronavirus surge MORE when he was diagnosed with COVID-19. 

In announcing the recommendations, WHO said its panel acknowledged the certainty of the evidence they are using is low, because it was only data currently available, and the evidence may become stronger as more becomes available over time.

“But given the remaining possibility of harm, as well as the relatively high cost and resource implications associated with remdesivir, they judged this to be an appropriate recommendation,” the WHO said.

They also support continued enrollment into trials evaluating remdesivir, especially to provide higher certainty of evidence for specific groups of patients.

In the U.S., manufacturer Gilead charges private insurers $3,120 per patient for a five-day course of the treatment.

Other developed countries and direct purchasers in the U.S. government, including Veterans Affairs hospitals, will pay $2,340 for a five-day course of the drug.



Source link

COMMENTS

Name

Africa,703,Americas,3718,Art & Culture,13882,Arts,6243,Arts & Design,1481,Asia,3051,Automobile,399,Baseball,485,Basketball,378,Books,3645,Business,5066,Celebrity,2532,Cricket,536,Crime,95,Cryptocurrency,1282,Dance,568,Defense,746,Diplomatic Relations,2414,Economy,972,Editorial,260,Education,1077,Elections,287,Energy & Environment,2922,Entertainment,21650,Environment,3393,Europe,3968,Faith & Religion,184,Family & Life,719,Fashion & Style,3002,Finance,18352,Food & Drink,3503,Football,999,Games,59,Gossip,10165,Health & Fitness,3817,Health Care,774,Hockey,165,Home & Garden,823,Humour,851,Latin America,49,Lifestyle,15710,Media,437,Middle East,1368,Movies,1557,Music,2419,Opinion,2548,Other,10710,Other Sports,4797,Political News,11064,Political Protests,2208,Politics,16918,Real Estate,1644,Relationship,59,Retail,3016,Science,2378,Science & Tech,9241,Soccer,138,Space & Cosmos,254,Sports,10937,Technology,3216,Tennis,489,Theater,1513,Transportation,236,Travel,2411,TV,3446,US Sports,1357,Video News,3531,War & Conflict,947,Weird News,930,World,15032,
ltr
item
Newsrust: WHO panel recommends against use of remdesivir for COVID-19 patients
WHO panel recommends against use of remdesivir for COVID-19 patients
https://thehill.com/sites/default/files/remdesivir.jpg
Newsrust
https://www.newsrust.com/2020/11/who-panel-recommends-against-use-of.html
https://www.newsrust.com/
https://www.newsrust.com/
https://www.newsrust.com/2020/11/who-panel-recommends-against-use-of.html
true
732247599994189300
UTF-8
Loaded All Posts Not found any posts VIEW ALL Readmore Reply Cancel reply Delete By Home PAGES POSTS View All RECOMMENDED FOR YOU LABEL ARCHIVE SEARCH ALL POSTS Not found any post match with your request Back Home Sunday Monday Tuesday Wednesday Thursday Friday Saturday Sun Mon Tue Wed Thu Fri Sat January February March April May June July August September October November December Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec just now 1 minute ago $$1$$ minutes ago 1 hour ago $$1$$ hours ago Yesterday $$1$$ days ago $$1$$ weeks ago more than 5 weeks ago Followers Follow THIS PREMIUM CONTENT IS LOCKED STEP 1: Share to a social network STEP 2: Click the link on your social network Copy All Code Select All Code All codes were copied to your clipboard Can not copy the codes / texts, please press [CTRL]+[C] (or CMD+C with Mac) to copy Table of Content